Klin Farmakol Farm. 2005;19(3):182-185

BIOLOGICAL TREATMENT OF RHEUMATOID ARTHRITIS

David Suchý, doc. MUDr. Otto Mayer CSc
Oddělení klinické farmakologie, FN Plzeň

Cytokines are recommended for the treatment of active rheumatoid arthritis (RA) after treatment failure of other disease modifying antirheumatic drugs (DMARDs), of which methotrexate (MTX) is a commonly used example. TNF-alfa blocking agents or can be added to preexisting therapy or may replace previous DMARDs. TNF-alfa blocking agents differ in molecular structure, detailed mechanisms of action, pharmacokinetic properties etc. Infliximab is approved for treatment of RA in combination with MTX, both adalimumab and etanercept could be used in combination as well as in monotherapy. The data from clinical trials suggest, however that the combination of TNF-alfa blocking agents and MTX yields superior results.

Keywords: Key words: rheumatoid arthritis, TNF-alfa monoclonal antibodies, pharmacological differences, therapeutic indications, combination therapy.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchý D, Mayer O. BIOLOGICAL TREATMENT OF RHEUMATOID ARTHRITIS. Klin Farmakol Farm. 2005;19(3):182-185.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brennan FM, Maini RN, Feldmann M. TNF-? - pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293-298. Go to original source... Go to PubMed...
    2. Choy EHS, Panay GS. Cytokine pathways and point inflammation in rheumatoid arthritis. N Engl J Med 2001; 344 (12): 907-916. Go to original source... Go to PubMed...
    3. Fox D. Cytokine blockade as a new strategy to treat rheumatoid arthritis. Inhibition of TNF. Arch Int Med 2000; 160: 437-444. Go to original source... Go to PubMed...
    4. Calabrese LH. Molecular differences in anticytokine therapies: Clin. Exp. Rheumatol. 2001; 21: 241-248.
    5. www.rx-list.com
    6. Maini RN, Breedweld FC, Walden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor of monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563. Go to original source...
    7. Lipsky PE, van der Heide, St Clair, et al. Anti tumor necrosis factor trial in RA with concomitant therapy study groups. Infliximab and MTX in the treatment of RA. N Engl J Med 2000; 343: 1594-1602. Go to original source... Go to PubMed...
    8. Mikuls TR, Weaver AL. Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Current Rheumatology Reports 2003; 5: 270-277. Go to original source... Go to PubMed...
    9. Van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense.
    10. Putte LBA, Rau R, Breedveld FC et al. Efficacy and safety of the fully human anti tumor necrosis factor ? monoclonal antibody adalimumab (D2E7) in DMARD refractory patiens with rheumatoid arthritis: a 12 week, phase II study Ann Rheum Dis 2003; 62: 1168-1177. Go to original source... Go to PubMed...
    11. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Arthritis Rheum. 1971; 14: 706-720. Go to original source... Go to PubMed...
    12. Weinblatt ME, Keystone EC, Furst DE. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for treatment of rheumatoid arthritis in patiens taking concommitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45. Go to original source... Go to PubMed...
    13. Furst D, Schiff M, Fleischmann R, et al. Adalimumab, a fully human anti tumor necrosis factor- ? monoclonal antibody, concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30: 2563-2571. Go to PubMed...
    14. Keystone E, Kavanaugh A, Sharp J, et al. Adalimumab (D2E7), a fully human anti-TNF-? monoclonal antibody, inhibits the progression of structural point damage in patiens with active RA despite concommitant methotrexate therapy. Abstract of paper presented at: ACR Annual Meeting, October 2002 New Orleans, LA.
    15. Van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patiens with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004; 63: 508-516. Go to original source... Go to PubMed...
    16. Abbott Comp., data on file
    17. Weiblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patiens with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259. Go to original source... Go to PubMed...
    18. Jarvis B, Faulds D. Etanercept. A rewiew of its use in RA. Drugs 1999; 945-966. Go to original source... Go to PubMed...
    19. Green GS. Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 2000; 59: i46-i49. Go to original source... Go to PubMed...
    20. Martin R, Ruderman E, Fleischmann R, et al. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial) - Ann Rheum Dis 2000; 59 (sSppl -I): 48.
    21. Genovese MC, Bathon JM, Martin RW, et al. Etanercept vs methotrexate in patiens with early rheumatoid arthritis. Two years radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-1450. Go to original source... Go to PubMed...
    22. Mohan N, Edwards T, Cupps TR, et al. Demyelination occuring during anti-tumor necrosis factor alpha therapy for inflammatory arthritis. Arthritis Rheum 2001; 44: 2862-2869. Go to original source...
    23. Tegzová D, Vencovský J, Hrba J, et al. Nežádoucí účinky léků používaných v revmatologii a základní principy jejich bezpečnosti II. Klin Farmakol Farm 2004; 18: 30-37.
    24. Vencovský J, Tegzová D, Pavelka K. Doporučení České revmatologické společnosti k biologické léčbě blokádou TNF - doplněk standardních léčebných postupů u revmatoidní artritidy. Čes Revmatol 2004; 12: 20-29.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.